93Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Argentina
Neuroscience Intelligence
Argentina neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #30 of 50 · Data maturity A · Research score 34.5 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
30Recruiting trials
24Publications
49Institutions
Executive interpretation
Argentina ranks #30 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC126 recruiting
Hoffmann-La Roche124 recruiting
Eli Lilly and Company51 recruiting
GlaxoSmithKline50 recruiting
Pfizer40 recruiting
Washington University School of Medicine33 recruiting
Genzyme, a Sanofi Company30 recruiting
Boehringer Ingelheim30 recruiting
Novartis Pharmaceuticals31 recruiting
Janssen Research & Development, LLC20 recruiting
Disease activity
Alzheimers25trials
Parkinsons14trials
Epilepsy10trials
Multiple Sclerosis7trials
Schizophrenia7trials
Other Neurology5trials
Depression5trials
Neuromuscular4trials
Migraine Headache3trials
Stroke3trials
Research institutions
Instituto Universitario de Ciencias de la Salud - Fundación Héctor A. BarcelóOpenAlexlinked institution
Universidad Torcuato Di TellaOpenAlexlinked institution
Fundación Ciencias Exactas y NaturalesOpenAlexlinked institution
Garrahan HospitalOpenAlexlinked institution
Centro Científico Tecnológico - Santa FeOpenAlexlinked institution
National University of Mar del PlataOpenAlexlinked institution
Instituto Multidisciplinario de Biología VegetalOpenAlexlinked institution
Universidad Abierta InteramericanaOpenAlexlinked institution
Instituto de Física de Buenos AiresOpenAlexlinked institution
Universidad Nacional del LitoralOpenAlexlinked institution
Clinical evidence trail
NCT07845253Effect of Limosilactobacillus Reuteri on Social Deficits in Children With Autistic Spectrum DisorderNOT_YET_RECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07170150A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseRECRUITING
NCT07033494A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)RECRUITING
NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RECRUITING
NCT06976216A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseRECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06887192A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRECRUITING
NCT06744920A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia GravisRECRUITING
Research evidence trail
PUBMEDRetinal nerve fiber layer and ganglion cell layer thinning as biomarkers of cognitive decline in multiple sclerosis: an 18-month prospective cohort study.2026-11-01
PUBMEDWWOX-related developmental and epileptic encephalopathy (WOREE): A case series of seven patients from Argentina.2026-11-01
PUBMEDDelays in treatment escalation after failure in multiple sclerosis: the role of therapy type and healthcare system.2026-10-17
PUBMEDDisrupted emotional neural synchrony in schizophrenia revealed by intersubject correlation of naturalistic fMRI.2026-10-01
PUBMEDRadiosurgical management of trigeminal neuralgia; Differences in outcomes between proximal and distal targeting: Meta-analysis of 1055 patients.2026-09-19
PUBMEDBetaII-spectrin gaps and patches emerge from the patterned assembly of the actin/spectrin membrane skeleton in human motor neuron axons.2026-09-08
PUBMEDFrom Severe Neonatal Encephalopathy to Slowly Neurologic Progressive Disease: Pyruvate Dehydrogenase Deficiency Related to PDHA1 Variants.2026-09-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.